Artelo Biosciences’ (ARTL) Buy Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Artelo Biosciences (NASDAQ:ARTL) in a research report report published on Tuesday,Benzinga reports. They currently have a $5.00 price target on the stock. HC Wainwright also issued estimates for Artelo Biosciences’ FY2025 earnings at ($1.84) EPS.

Several other research firms have also weighed in on ARTL. LADENBURG THALM/SH SH raised shares of Artelo Biosciences to a “strong-buy” rating in a report on Wednesday, December 25th. D. Boral Capital restated a “buy” rating and set a $6.00 price target on shares of Artelo Biosciences in a research report on Thursday, February 27th.

Artelo Biosciences Stock Performance

NASDAQ ARTL opened at $1.00 on Tuesday. The firm has a market capitalization of $3.23 million, a P/E ratio of -0.35 and a beta of 1.06. The stock has a 50-day simple moving average of $1.17 and a two-hundred day simple moving average of $1.15. Artelo Biosciences has a fifty-two week low of $0.91 and a fifty-two week high of $1.70.

Artelo Biosciences (NASDAQ:ARTL) last posted its earnings results on Monday, March 3rd. The company reported ($1.17) EPS for the quarter, missing the consensus estimate of ($0.74) by ($0.43). As a group, analysts forecast that Artelo Biosciences will post -2.62 earnings per share for the current year.

About Artelo Biosciences

Artelo Biosciences, Inc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders.